INVO Bioscience Investor Presentation — November 2019 - INVO Bioscience

Document content

A SIMPLER WAY TO LIFE

November 2019CORPORATE PRESENTATIONOTC QB: IVOBThis presentation includes forward -looking statements within the meaning of Section 27A of the

Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended. All statements regarding our expected future financial position, results of operations,

cash flows, financing plans, business strategies, products and services, competitive positions,

growth opportunities, plans and objectives of management for future operations, as well as

statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect,"

"intend," "may," "could," "should," "will," and other similar expressions are forward -looking

statements. All forward -looking statements involve risks, uncertainties and contingencies, many of

which are beyond our control, which may cause actual results, performance, or achievements to

differ materially from anticipated results, performance, or achievements. Factors that may cause

actual results to differ materially from those in the forward -looking statements include those set

forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such

obligation to) update or alter our forward -looking statements, whether as a result of new

information, future events or otherwise.INVO BIOSCIENCE –Developer and manufacturer of the INVOcell ™

•Patented , Innovative medical device technology

•FDA Cleared –in November 2015 through the De Novo pathway

•Worlds only in vivo Intravaginal culture (IVC) system -a disruptive new fertility

treatment alternative

●LARGE & UNDER SERVED MARKET –Global infertility market estimated at $20+

billion currently, despite only 1% to 2% of the estimated 150M infertile couples

currently treated due primarily to cost and access.

●SIGNED EXCLUSIVE U.S. LICENSING AGREEMENT WITH FERRING IN JAN 2019

●$5.0 million up front plus $3.0 million in additional milestone payments

●Required minimum annual revenue over the next seven (7) years.

●INITIAL COMMERCIALIZATION EFFORTS WITH FERRING UNDERWAY

●498% revenue growth in Q2 2019

●Available in approximately 100 clinics in more than 20 states

●Increasing media coverage

●INTERNATIONAL COMMERCIALIZATION EFFORTS BEGININGCOMPANY OVERVIEW

Preview truncated — download the full document for the complete content.